Chemical formula: C₁₄H₁₉N₅O₄S Molecular mass: 353.4 g/mol PubChem compound: 24764487
Gefapixant interacts in the following cases:
Dose adjustment is required in patients with severe renal impairment (eGFR <30 mL/minute/1.73 m²) not requiring dialysis. The dose should be reduced to one 45 mg taken once daily.
Insufficient data are available in patients with end-stage renal disease requiring dialysis to make dosing recommendations.
Treatment with gefapixant should be evaluated and individualised in patients who develop an acute lower respiratory tract infection.
In patients with moderate to severe obstructive sleep apnoea (OSA, n=19) who were not using positive airway pressure (PAP), gefapixant 180 mg daily at bedtime was associated with a lower mean SaO2 and a higher mean proportion of time with SaO2 <90% across all sleep stages compared to placebo. The clinical relevance of these findings for the use of 45 mg gefapixant twice daily in patients with refractory chronic cough (RCC) or unexplained chronic cough (UCC) with comorbid OSA is not known. For patients with OSA, appropriate treatment for OSA should be considered prior to initiating treatment with gefapixant.
Gefapixant contains a sulphonamide moiety but is considered to be a non-sulphonylarylamine. Gefapixant has not been studied in patients with a history of hypersensitivity to sulphonamide, therefore, cross-hypersensitivity with sulphonamide hypersensitivity cannot be excluded. Gefapixant should be used with caution in patients with known hypersensitivity to sulphonamides.
There are no data from the use of gefapixant in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. As a precautionary measure, it is preferable to avoid the use of gefapixant during pregnancy and in women of childbearing potential not using contraception.
Available pharmacodynamic/toxicological data in animals have shown excretion of gefapixant in milk.
A risk to newborns/infants cannot be excluded.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from gefapixant therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
No human data on the effect of gefapixant on fertility are available. In rats, there was no effect on mating or fertility with gefapixant treatment.
Gefapixant has no or negligible influence on the ability to drive and use machines. In individual cases, dizziness may occur following administration of gefapixant that may influence the ability to drive and use machines.
The most frequently reported adverse reactions were dysgeusia (41%), ageusia (15%), and hypogeusia (11%).
The safety of gefapixant was evaluated in two phase III clinical studies (COUGH-1 and COUGH-2) which included a total of 1,369 patients treated with gefapixant (15 mg or 45 mg twice daily). The duration of exposure with gefapixant was 52 weeks.
The adverse reactions reported with gefapixant obtained from clinical studies are listed in the table below by MedDRA system organ class and by frequency. Frequencies are defined as very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), and very rare (<1/10,000).
Adverse reactions:
System Organ Class | Adverse reactions |
---|---|
Infections and infestations | |
Common | Upper respiratory tract infection |
Metabolism and nutrition disorders | |
Common | Decreased appetite |
Nervous system disorders | |
Very Common | Dysgeusia*, Ageusia, Hypogeusia |
Common | Taste disorder, Dizziness |
Respiratory, thoracic and mediastinal disorders | |
Common | Cough**, Oropharyngeal pain |
Gastrointestinal disorders | |
Common | Nausea, Diarrhoea, Dry mouth, Salivary hypersecretion, Abdominal pain upper, Dyspepsia, Hypoaesthesia oral, Paraesthesia oral |
Psychiatric disorders | |
Common | Insomnia |
Renal and urinary disorders | |
Uncommon | Calculus urinary, Nephrolithiasis, Calculus bladder |
* Dysgeusia was commonly reported as taste bitter, taste metallic or taste salty.
** Cough includes reports of ‘worsening’, ‘exacerbation’, ‘increase’, or ‘increased’ cough.
The majority of patients with taste-related adverse reactions (dysgeusia, ageusia, hypogeusia and taste disorder) experienced the onset of the adverse reactions within 9 days of starting gefapixant; the majority were mild (65%) to moderate (32%) in intensity. Resolution of the taste-related adverse reactions occurred in 96% of patients with 25% reporting resolution on or before the last dose of gefapixant. Taste-related adverse reactions persisted for more than a year after discontinuation in 1.6% (7/447) of patients in the gefapixant group and 12.8% (6/47) of patients in the placebo group. Adverse reactions resulting in discontinuation occurred in 22% of patients receiving gefapixant. The most frequently reported adverse reactions leading to discontinuation of treatment were dysgeusia (9%) and ageusia (4%).
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.